Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials.
Sherry AD, Lin TA, McCaw ZR, Beck EJ, Kouzy R, Abi Jaoude J, Passy AH, Miller AM, Kupferman GS, Fuller CD, Thomas CR Jr, Koay EJ, Tang C, Msaouel P, Ludmir EB. Sherry AD, et al. Among authors: msaouel p. Int J Radiat Oncol Biol Phys. 2024 Dec 1;120(5):1239-1244. doi: 10.1016/j.ijrobp.2024.05.033. Epub 2024 Sep 30. Int J Radiat Oncol Biol Phys. 2024. PMID: 39352322
Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy.
Sherry AD, Msaouel P, McCaw ZR, Abi Jaoude J, Hsu EJ, Kouzy R, Patel R, Yang Y, Lin TA, Taniguchi CM, Rödel C, Fokas E, Tang C, Fuller CD, Minsky B, Meirson T, Sun R, Ludmir EB. Sherry AD, et al. Among authors: msaouel p. Eur J Cancer. 2023 Nov;194:113357. doi: 10.1016/j.ejca.2023.113357. Epub 2023 Sep 22. Eur J Cancer. 2023. PMID: 37827064 Free PMC article.
Association of differential censoring with survival and suboptimal control arms among oncology clinical trials.
Hsu EJ, Lin TA, Dabush DR, McCaw Z, Koong A, Lin C, Abi Jaoude J, Patel R, Kouzy R, El Alam MB, Noticewala S, Yang Y, Sherry AD, Fuller CD, Thomas CR Jr, Tang C, Msaouel P, Das P, Huang B, Tian L, Sun R, Lee JJ, Meirson T, Ludmir EB. Hsu EJ, et al. Among authors: msaouel p. J Natl Cancer Inst. 2024 Jun 7;116(6):990-994. doi: 10.1093/jnci/djae028. J Natl Cancer Inst. 2024. PMID: 38331394
[No title available]
[No authors listed] [No authors listed] PMID: 38579843
Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients.
Lebenthal JM, Kontoyiannis PD, Hahn AW, Lim ZD, Rao P, Cheng JP, Chan B, Daw NC, Sheth RA, Karam JA, Tang C, Tannir NM, Msaouel P. Lebenthal JM, et al. Among authors: msaouel p. Eur Urol Oncol. 2024 Jul 15:S2588-9311(24)00175-5. doi: 10.1016/j.euo.2024.07.002. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39013742
Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy.
Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Hahn AW, et al. Among authors: msaouel p. Eur Urol Focus. 2023 Sep;9(5):734-741. doi: 10.1016/j.euf.2023.02.008. Epub 2023 Feb 28. Eur Urol Focus. 2023. PMID: 36863962 Free PMC article.
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
Msaouel P, Sweis RF, Bupathi M, Heath E, Goodman OB Jr, Hoimes CJ, Milowsky MI, Davis N, Kalebasty AR, Picus J, Shaffer D, Mao S, Adra N, Yorio J, Gandhi S, Grivas P, Siefker-Radtke A, Yang R, Latven L, Olson P, Chin CD, Der-Torossian H, Mortazavi A, Iyer G. Msaouel P, et al. Eur Urol Oncol. 2024 Aug;7(4):933-943. doi: 10.1016/j.euo.2023.12.001. Epub 2023 Dec 16. Eur Urol Oncol. 2024. PMID: 38105142 Clinical Trial.
205 results